Zacks: Brokerages Anticipate Chemours Co (NYSE:CC) Will Post Earnings of $0.43 Per Share

Analysts expect Chemours Co (NYSE:CC) to report $0.43 earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have issued estimates for Chemours’ earnings, with the highest EPS estimate coming in at $0.46 and the lowest estimate coming in at $0.37. Chemours reported earnings per share of $1.05 in the same quarter last year, which indicates a negative year over year growth rate of 59%. The company is scheduled to announce its next quarterly earnings results after the market closes on Thursday, February 13th.

On average, analysts expect that Chemours will report full-year earnings of $2.37 per share for the current fiscal year, with EPS estimates ranging from $2.32 to $2.40. For the next fiscal year, analysts expect that the business will report earnings of $3.10 per share, with EPS estimates ranging from $2.70 to $3.60. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Chemours.

Chemours (NYSE:CC) last released its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.03. The business had revenue of $1.39 billion during the quarter, compared to analyst estimates of $1.40 billion. Chemours had a net margin of 7.24% and a return on equity of 58.38%. Chemours’s revenue was down 14.6% compared to the same quarter last year. During the same period last year, the business earned $1.49 EPS.

CC has been the subject of a number of analyst reports. Cfra upgraded shares of Chemours from a “hold” rating to a “buy” rating in a research note on Wednesday, November 6th. UBS Group reduced their price objective on shares of Chemours from $19.00 to $14.50 and set a “neutral” rating for the company in a research note on Wednesday, October 2nd. Royal Bank of Canada restated a “hold” rating and set a $19.00 price objective on shares of Chemours in a research note on Sunday, December 22nd. JPMorgan Chase & Co. reduced their price objective on shares of Chemours from $21.00 to $19.00 and set a “neutral” rating for the company in a research note on Friday, December 20th. Finally, ValuEngine upgraded shares of Chemours from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $23.15.

NYSE:CC traded down $0.59 on Friday, reaching $15.59. 2,770,962 shares of the stock traded hands, compared to its average volume of 2,158,042. The company has a market capitalization of $2.65 billion, a price-to-earnings ratio of 6.52, a PEG ratio of 0.34 and a beta of 2.55. The company has a current ratio of 1.72, a quick ratio of 0.98 and a debt-to-equity ratio of 5.05. Chemours has a 12 month low of $11.71 and a 12 month high of $41.60. The company’s fifty day simple moving average is $17.33 and its 200 day simple moving average is $16.36.

Several hedge funds have recently made changes to their positions in CC. First Trust Advisors LP grew its stake in shares of Chemours by 40.1% in the first quarter. First Trust Advisors LP now owns 117,670 shares of the specialty chemicals company’s stock worth $4,373,000 after acquiring an additional 33,696 shares during the period. HighTower Advisors LLC grew its stake in shares of Chemours by 14.7% in the second quarter. HighTower Advisors LLC now owns 56,671 shares of the specialty chemicals company’s stock worth $1,356,000 after acquiring an additional 7,277 shares during the period. Nomura Asset Management Co. Ltd. grew its stake in shares of Chemours by 21.9% in the second quarter. Nomura Asset Management Co. Ltd. now owns 36,393 shares of the specialty chemicals company’s stock worth $873,000 after acquiring an additional 6,531 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Chemours by 183.5% in the second quarter. Tower Research Capital LLC TRC now owns 14,837 shares of the specialty chemicals company’s stock worth $356,000 after acquiring an additional 9,604 shares during the period. Finally, NumerixS Investment Technologies Inc bought a new stake in shares of Chemours in the second quarter worth approximately $202,000. Hedge funds and other institutional investors own 76.22% of the company’s stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Read More: What is a Call Option?

Get a free copy of the Zacks research report on Chemours (CC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.